Analytical range LOQ [Bioanalytics]

posted by Farmacevt – North Macedonia, 2021-12-22 22:02 (150 d 23:04 ago) – Posting: # 22711
Views: 672

Thanks,
But when you say:

» At one extreme you may need to eliminate those subject periods that are affected, which may mean a complete loss of a subject for stats if this is a 222BE design, since only subjects who contribute with T and R should be in the stats analysis.

What is the rational for eliminating those subjects? According to my opinion excluding these subjects can not show that the subjects might have had pre-dose concentration below the LOQ with the given method. It will only reduce the power of the study, isn't it?


Edit: Standard quotes restored; see also this post #8[Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
22,091 posts in 4,630 threads, 1,566 registered users;
online 19 (0 registered, 19 guests [including 18 identified bots]).
Forum time: Sunday 22:06 CEST (Europe/Vienna)

Competence, like truth, beauty and contact lenses,
is in the eye of the beholder.    Laurence J. Peter

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5